Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

[Tolerance of biological agents in children].

Bader-Meunier B.

Arch Pediatr. 2010 Jun;17(6):962-3. doi: 10.1016/S0929-693X(10)70199-8. Review. French. No abstract available.

PMID:
20654981
[PubMed - indexed for MEDLINE]
2.

Pediatric rheumatology: JIA, treatment and possible risk of malignancies.

Ruperto N, Martini A.

Nat Rev Rheumatol. 2011 Jan;7(1):6-7. doi: 10.1038/nrrheum.2010.199. Epub 2010 Dec 7. No abstract available.

PMID:
21135880
[PubMed - indexed for MEDLINE]
3.

Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.

Tarkiainen M, Tynjälä P, Vähäsalo P, Lahdenne P.

Scand J Rheumatol. 2011 Mar;40(2):150-2. doi: 10.3109/03009742.2010.499878. Epub 2010 Sep 26. No abstract available.

PMID:
20868307
[PubMed - indexed for MEDLINE]
4.

Adalimumab in juvenile rheumatoid arthritis.

Taddio A, Marchetti F.

N Engl J Med. 2008 Dec 4;359(23):2495-6; author reply 2496-7. No abstract available.

PMID:
19065749
[PubMed - indexed for MEDLINE]
5.

[Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Horneff G.

Z Rheumatol. 2010 Aug;69(6):516-26. doi: 10.1007/s00393-010-0655-8. Review. German.

PMID:
20532787
[PubMed - indexed for MEDLINE]
6.

Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.

Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.

J Rheumatol. 2011 Oct;38(10):2258-63. doi: 10.3899/jrheum.110145. Epub 2011 Aug 15.

PMID:
21844151
[PubMed - indexed for MEDLINE]
7.

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.

Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.

Int J Rheum Dis. 2012 Jun;15(3):330-5. doi: 10.1111/j.1756-185X.2012.01715.x. Epub 2012 Feb 13.

PMID:
22709496
[PubMed - indexed for MEDLINE]
8.

Tumor necrosis factor blockers in rheumatoid arthritis.

Pisetsky DS.

N Engl J Med. 2000 Mar 16;342(11):810-1. No abstract available.

PMID:
10717018
[PubMed - indexed for MEDLINE]
9.

Biologicals in the treatment of psoriasis.

Boker A, Kimball AB, Rolz-Cruz G.

Curr Opin Investig Drugs. 2007 Nov;8(11):939-46. Review.

PMID:
17979028
[PubMed - indexed for MEDLINE]
10.

When should we use TNF antagonists in children with rheumatic disease?

Quartier P.

Joint Bone Spine. 2007 Jan;74(1):1-3. Epub 2006 Nov 13. No abstract available.

PMID:
17174585
[PubMed - indexed for MEDLINE]
11.

[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].

Sánchez-Regaña M, Dilmé E, Puig L, Bordas X, Carrascosa JM, Ferran M, Herranz P, García-Bustinduy M, López Estebaranz JL, Alsina M, Rodríguez MA, Ribera M, Fernández-López E, Moreno JC, Belinchón Romero I, Vidal D; Grupo Español de Psoriasis de la Academia Española.

Actas Dermosifiliogr. 2010 Mar;101(2):156-63. Spanish.

PMID:
20223158
[PubMed - indexed for MEDLINE]
12.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
[PubMed - indexed for MEDLINE]
13.

Tumor necrosis factor antagonists in the therapy of psoriasis.

Mössner R, Schön MP, Reich K.

Clin Dermatol. 2008 Sep-Oct;26(5):486-502. doi: 10.1016/j.clindermatol.2007.10.030. Review.

PMID:
18755367
[PubMed - indexed for MEDLINE]
14.

[The importance of biologicals in the treatment of SoJIA].

Dückers G, Niehues T.

Z Rheumatol. 2010 Aug;69(6):505-15. doi: 10.1007/s00393-010-0635-z. Review. German.

PMID:
20668866
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.

Viguier M, Aubin F, Delaporte E, Pagès C, Paul C, Beylot-Barry M, Goujon C, Rybojad M, Bachelez H; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.

Arch Dermatol. 2012 Dec;148(12):1423-5. doi: 10.1001/2013.jamadermatol.80. No abstract available.

PMID:
23247492
[PubMed - indexed for MEDLINE]
17.

[Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].

Sauvain MJ, Schalm SB, Bérthet G, Bolz D, Cannizzaro E, Hofer M, Kaiser D, Saurenmann RK, Bolt IB.

Praxis (Bern 1994). 2010 May 26;99(11):649-54. doi: 10.1024/1661-8157/a000144. German.

PMID:
20506089
[PubMed - indexed for MEDLINE]
18.

Infections during treatment with biological agents and possible treatment in clinical practice.

Atzeni F, Benucci M, Sarzi-Puttini P.

Expert Rev Clin Immunol. 2013 Mar;9(3):193-5. doi: 10.1586/eci.13.3. No abstract available.

PMID:
23445193
[PubMed - indexed for MEDLINE]
19.

Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy.

Varley CD, Deodhar AA, Ehst BD, Bakke A, Blauvelt A, Vega R, Yamashita S, Winthrop KL.

Rheumatology (Oxford). 2014 Feb;53(2):332-7. doi: 10.1093/rheumatology/ket351. Epub 2013 Oct 29.

PMID:
24173434
[PubMed - indexed for MEDLINE]
20.

[Introduction to biological drugs].

Fernández-Cruz E, Alecsandru D, Rodríguez-Sainz C.

Actas Dermosifiliogr. 2008 Jul;99 Suppl 4:2-6. Review. Spanish.

PMID:
19080985
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk